Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Shoring Up the ACA; Alzheimer's Drugs; Hispanics in Clinical Trials
July 19, 2017 – AJMC Staff
Is Complete Lymph Node Dissection Essential in Melanoma?
July 18, 2017 – Surabhi Dangi-Garimella, PhD
Without Votes for BCRA, McConnell Calls for Repeal and Delay of ACA
July 18, 2017 – Laura Joszt
Four Republicans Now Oppose Senate Healthcare Bill
July 18, 2017 – Laura Joszt
What We're Reading: Medicare Forecast; Handwritten Prescription Errors; Repeal Back-up Plan
July 14, 2017 – AJMC Staff
High Fat Diet Reduces Gut Bacteria and Fights Against Crohn's Disease
July 14, 2017 – Alison Rodriguez
FDA Advisory Committee Confirms Support for Biosimilars to Trastuzumab, Bevacizumab
July 13, 2017 – Surabhi Dangi-Garimella, PhD
Study Suggests New Vaccine Can Lower Cholesterol, Immunize Against CVD
July 13, 2017 – Alison Rodriguez
Novartis' CAR-T Therapy, CTL019, Approved 10-0 by FDA's ODAC
July 12, 2017 – Surabhi Dangi-Garimella, PhD

What We're Reading: Shoring Up the ACA; Alzheimer's Drugs; Hispanics in Clinical Trials

AJMC Staff

Schumer Offers ACA Fixes

With not enough Senate Republicans on board to pass legislation to repeal and replace, or even just repeal, the Affordable Care Act (ACA), Senate Minority Leader Charles Schumer (D-New York) is offering is own ideas on how to proceed. According to The Washington Post, Schumer has provided 3 ways Democrats and Republicans can work together to fix the ACA. However, he did tell his party members that no deals can include tax cuts for wealthy Americans or cuts to Medicaid.

 

Alzheimer’s Drug Pipeline Booming

The last Alzheimer’s drug to be approved in the United States was in 2003, but that may change soon. There are 27 drugs to treat Alzheimer’s disease in phase 3 clinical trials. Overall, researchers expect nearly 3 dozen new drugs could reach the market in the next 5 years, despite decades of failed drugs in the space and underinvestment. By 2050, there could be as many as 16 million Americans with Alzheimer’s disease.

 

Few Hispanics Participate in Clinical Trials

A report from Kaiser Health News highlighted how Hispanics are often left out of clinical trials, with detrimental effects. Enrollment in clinical trials provides access to experimental, cutting-edge treatments, which means they could be left out of getting access to potential cures. In addition, lack of representation in clinical trials means researchers have less data on how drugs work among Hispanics. A new campaign from the FDA is trying to fix the situation by educating Hispanics about medical studies.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up